Latest research on BPC-157
A rolling research summary page that can be updated as new papers or reviews emerge.
Articles
Editorial coverage
Long-form pieces that expand on peptide topics without fragmenting the site into thin, overlapping pages.
Peptide gels that act like depots
Peptide drugs fail for a boring reason: delivery. Self-assembling peptide hydrogels try to fix that by turning peptides into local depots that hold and release medicine over time.
What to know about melanotan II
Melanotan II is an unapproved “tanning peptide” that stimulates melanin signaling. The hard part is not the biology. It’s the safety, skin-risk, and unregulated supply chain.
Kisspeptin and gonadorelin: upstream hormone signals, not casual wellness tools
Kisspeptin and gonadorelin have real clinical lineage, but they sit high in the hormone control system. If use expands through compounding channels, careful monitoring and conservative claims will matter.
Peptides on surfaces, not injections: the biomaterials play
Some of the most practical peptide ‘therapies’ aren’t injections at all. They’re tiny signals tethered to materials, designed to help healing happen in the right place.
What looser peptide compounding rules would actually change
If FDA expands which peptides can be compounded, the biggest effects will likely be supply-chain, liability, and access shifts, not an overnight jump in evidence quality.
Peptides 101
A plain-language guide to what peptides are, why people care, and how to read this site.
How peptide hype evolves (and a verification checklist)
A practical field guide to how new peptides and ‘next-gen analogs’ spread online, what usually gets exaggerated, and the minimum evidence needed before you treat marketing as reality.
Peptides that can dial down cortisol
A few human peptides have evidence for blunting cortisol responses in specific settings. This is what we actually know, what’s still unclear, and why ‘lower cortisol’ is a tricky goal.
Russian peptide bioregulators: from military medicine to wellness marketing
A history-first tour of the Russian peptide-bioregulator ecosystem, from organ extracts and military-medical institutions to tripeptides like Pinealon (EDR), patents, and modern online folklore.
Why peptides feel like magic (and what they actually are)
Peptides can look like biological spells: tiny molecules that seem to fix unrelated problems. The real story is messier and more useful: specificity, delivery constraints, and the evidence ladder.
The facts behind Reta
Retatrutide, often called “Reta,” is an investigational triple-agonist weight-loss drug. Early trials look impressive, but the main questions are long-term safety, tolerability, and what happens outside tightly run studies.